kcn@scripps.edu Received July 7, 1999



ABSTRACT

PhSe-X

O—Se-X SnCl₄, -23 °C (65-98%)

Garsubellin A (1, Figure 1) is a polyisoprenylated phloroglucinol derivative from Garcinia subelliptica found on the Okinawa Islands of Japan.¹ It is characterized by a highly oxygenated and densely substituted bicyclo[3.3.1]nonane-1,3,5-trione core fused to a tetrahydrofuran ring and appended with lipophilic side chains. Interest in garsubellin A (1) stems from its in vitro neurotrophic properties making it a potential candidate for the treatment of neurodegenerative diseases.² The potential importance of garsubellin A(1) to biology and medicine prompted us to pursue a total synthesis,³ the success of which was contingent upon developing a reliable methodology for constructing its unusual bicyclic skeleton. Moreover, since the core of garsubellin A(1) is conserved among a number of other natural products of the Guttiferae classification,⁴ including nemorosone II^5 (2), a versatile construction of this framework might find application in future synthetic investigations of this biologically diverse



Figure 1. Structure of garsubellin A (1) and nemorosone II (2).

family of compounds. Herein we describe an improved method for the construction of the 2,2-dimethylbicyclo[3.3.1]-nonan-9-one carbon framework of these molecules.

From a synthetic vantage point, one of the challenging features of this skeleton is the highly congested C-1 through C-3 region (Figure 1) with a quaternary *gem*-dimethyl group at C-2 flanked by a quaternary bridgehead carbon (C-1) and a tertiary prenylated carbon (C-3). This congestion, compounded by the fact that the remaining bridgehead position (C-5) is also quaternary, essentially precludes construction

K. C. Nicolaou,* Jeffrey A. Pfefferkorn, Guo-Qiang Cao, Sanghee Kim, and Jilali Kessabi

A Facile Method for the Solution and

Solid-Phase Synthesis of Substituted

[3.3.1] Bicycles

Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, and Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 kcn@scripps.edu



ORGANIC LETTERS

⁽¹⁾ Fukuyama, Y.; Kuwayama, A.; Minami, H. Chem. Pharm. Bull. 1997, 45, 947–949.

⁽²⁾ Hefti, F. J. Annu. Rev. Pharmcol. Toxicol. **1997**, *37*, 239–267. Hefti, F. J. Neurobiol. **1994**, 1418–1435.

⁽³⁾ Nicolaou, K. C.; Pfefferkorn, J. A.; Kim, S.; Wei, H. J. Am. Chem. Soc. **1999**, 121, 4724–4725.

of this framework via the α, α' -annulation strategies traditionally employed in the construction of bicyclo[3.3.1]nonan-9-ones.⁶ In fact, there has been very little work reported on the synthesis of 2,2-dimethylbicyclo[3.3.1]nonan-9-ones with both bridgehead positions substituted as required for construction of the garsubellin A (1) skeleton.⁷ In light of this, we considered a strategy as outlined in the simplified retrosynthetic analysis of Scheme 1. Examination of the



^{*a*} Conditions: (a) 1.1 equiv of *N*-PSP, 1.0 equiv of SnCl₄, CH₂Cl₂, 0 °C 10 min; (b) 1.1 equiv of (SnCl₄, TiCl₄, ZnCl₂, AlCl₃, or BF₃OEt₂), CH₂Cl₂, 0 to 25 °C, 24 h; (c) Ac₂O, 4-DMAP, 80 °C, 30 min; (d) 1.1 equiv of *N*-PSP, 1.0 equiv of SnCl₄, CH₂Cl₂, -78 °C, 5 min. Abbreviations: 4-DMAP = 4-(dimethylamino)pyridine. *N*-PSP = *N*-(phenylseleno)phthalimide.

general skeleton **3** led to the realization that the C-3 substituent might be disconnected via a radical addition transform leading to intermediate **4** which revealed the retron for a powerfully simplifying selenium-induced endocyclization of a pendent olefin onto a suitably positioned β -dicarbonyl moiety. Such a cyclization would establish, in one step, the bicycle through construction of the sterically demanding

C-1-C-2 bond with concomitant installation of a radical precursor at C-3. Encouragingly, as shown in Scheme 1, Ley et al. had previously accomplished the construction of bicycle **8** by treatment of an allyl-substituted β -keto ester **6** with a variety of selenium donors and catalysts to initially afford the kinetically favored O-cyclized furan 7, which was subsequently equilibrated to the thermodynamically favored carbocycle 8.8 Thus, we constructed the corresponding prenylated β -keto ester model system 9 (Scheme 1) and using similar conditions, obtained the O-cyclized furan 10 in 88% yield. Unfortunately, furan 10 proved resistant toward equilibration to the desired 2,2-dimethylbicyclo[3.3.1]nonan-9-one 11 even upon prolonged exposure (24 h) to a variety of Lewis acids (see Scheme 1) resulting only in decomposition. This failure forced us to consider a strategy for masking the nucleophilicity of the enolic oxygen, thereby providing direct access to the desired carbocyclic product. We postulated that acetylation of the enolic oxygen would inhibit O-cyclization⁹ and, as proposed in intermediate 13, might lead to the desired C-cyclization through in situ, nucleophically assisted cleavage of the acetate during carbon-centered attack on a pendent epi-selenium complex. To test this hypothesis, we prepared enol acetate 12, and gratifyingly, upon treatment with N-(phenylseleno)phthalimide $(N-PSP)^{10}$ and SnCl₄ at -78 °C for 5 min, it underwent exclusive conversion to the desired carbocycle 11, in 94% yield.

Encouraged by the facility and selectivity of this cyclization at low temperature, we sought to determine its synthetic utility focusing on three criteria: (a) tolerance toward increasing substitution on the cyclohexane framework as required for the construction of various natural and designed products; (b) effect of olefin substitution on the regioselec-

(5) Oliveira, C. M. A.; Porto, A. L. M.; Bittrich, V.; Marsaioli, A. J. *Phytochemistry* **1999**, *50*, 1073–1079.

(6) For examples, see: Taeschler, C.; Sorenson, T. S. J. Org. Chem. **1998**, 63, 5704–5705. Harding, K. E.; Clement, B. A.; Moreno, L.; Katalinic, J. P. J. Org. Chem. **1981**, 46, 940–948. Padwa, A.; Kline, D. N.; Murphree, S. S.; Yeske, P. E. J. Org. Chem. **1992**, 57, 298–306. Peters, J. A. Synthesis **1979**, 321–336. Lu, X.; Huang, Y. Tetrahedron Lett. **1986**, 27, 1615–1616.

(7) To the best of our knowledge, no substituted 2,2-dimethylbicyclo-[3.3.1]nonan-9-one wherein both bridgehead positions are quaternary has been reported. For examples of the construction of substituted 2,2dimethylbicyclo[3.3.1]nonan-9-one with at least one quaternary bridgehead position, see: Firrel, N. F.; Hickmott, P. W.; Hopkins, B. J. J. Chem Soc. C 1970, 1477-1480. Dauben, W. G.; Bunce, R. A. J. Org. Chem. 1983, 48, 4642-4648. Gambacorta, A.; Fabrizi, G.; Bovicelli, P. Tetrahedron 1992, 48, 4459-4464. Evans, E. H.; Hewson, A. T.; March, L. A.; Nowell, I. W.; Wadsworth, A. H. J. Chem. Soc., Perkin Trans. 1 1987, 137-149.

(8) Jackson, W. P.; Ley, S. V.; Morton, J. A. J. Chem. Soc., Chem. Commun. **1980**, 1028–1029. Jackson, W. P.; Ley, S. V.; Whittle, A. J. J. Chem. Soc., Chem. Commun. **1980**, 1173–1174. Jackson, W. P.; Ley, S. V.; Morton, J. A. Tetrahedron Lett. **1981**, 22, 2601–2604.

(9) For precedent, see: Edstrom, E. D.; Livinghouse, T. J. Org. Chem. **1987**, 52, 951–953. Tamelen, E. E; Hwu, J. R.; Leiden, T. M. J. Chem. Soc., Chem. Commun. **1983**, 62–63. Evans, E. H.; Hewson, A. T.; Wadsworth, A. H. Synth. Comm. **1985**, 15, 243–247.

(10) Nicolaou, K. C.; Claremon, D. A.; Barnette, W. E.; Seitz, S. P. J. *Am. Chem. Soc.* **1979**, *101*, 3704–3706. Nicolaou, K. C.; Petasis, N. A.; Claremon, D. A. *Tetrahedron* **1985**, *41*, 4835–4841.

⁽⁴⁾ For examples, see: Gustafson, K. R.; Blunt, J. W.; Munro, M. H. G.; Fuller, R. W.; McKee, T. C.; Cardelina, J. H.; McMahon, J.; Gragg, G. M.; Boyd, M. R. *Tetrahedron* **1992**, *48*, 10093–10102. Iinuma, M.; Tosa, H.; Tanaka, T.; Kanamaru, S.; Asai, F.; Kobayashi, Y.; Miyauchi, K.; Shimano, R. *Biol. Pharm. Bull.* **1996**, *18*, 311–314. Alves, T. M. A.; Alves, R. O.; Romanha, A. J.; Santos, M. H.; Nagem, T. J.; Zani, C. L. J. Nat. Prod. **1999**, *62*, 369–371. Oliveira, C. M. A.; Porto, A. M.; Bittrich, V.; Vencato, I.; Marsaioli, A. J. *Tetrahedron Lett.* **1996**, *37*, 6427–6430.

tivity of the cyclization; and (c) applicability of solid-phase selenium reagents,¹¹ thereby allowing for construction of resin-bound bicycles applicable to solid-phase natural product and combinatorial synthesis.

We began by exploring the effects of increased substrate functionalization with an emphasis on constructing suitable frameworks for the total synthesis of garsubellin A (1), nemorosone II (2), and related natural products. Of primary interest were the lactone-functionalized systems of Table 1

Table 1. Construction of Frameworks for Bicyclic NaturalProducts from the Guttiferae Classification



 a Isolated yield after purification unless otherwise noted. b Yield at 40% conversion by $^1{\rm H}$ NMR of crude reaction mixture.

since the bicyclic products resulting from such substrates possessed the minimum functionality required for elaboration to these compounds (1 and 2), as we recently demonstrated by converting the product of substrate 14 to the fully substituted and oxygenated core of garsubellin A (1).³ As illustrated in Table 1, the cyclization was not hampered by the increased strain introduced by the fused lactone, and it nicely accommodated a variety of substituents including methoxy, methyl, isopropyl, phenyl, and even a conjugated olefin. Unlike the previous model systems, these more functionalized substrates required slightly higher temperatures (-23 °C) for optimal conversion. The only limitation noted was with substrate 16 as the increased steric demand of the isopropyl substituent caused the reaction to proceed sluggishly and never past 40% conversion. Attempts to increase conversion using higher reaction temperatures or longer reaction times resulted only in decomposition.

Cognizant of the presence of [3.3.1] bicycles in a host of other bioactive natural and designed structures, we sought to extend our studies. As an example we considered construction of a variety of fused aromatic bicycles such as those shown in Table 2. Since several natural products (e.g., selagine¹² and huperzine¹³) as well as several designed small molecule analgesics¹⁴ and anticonvulsants¹⁵ possess related skeletons, application of the current methodology would allow for the construction of conformationally constrained analogues.¹⁶ As shown in Table 2, the cyclization reaction

Table 2. Construction of Aryl-Fused

Bicyclo[3.3.1]nonan-9-ones via Selenium-Mediated Cyclizations



^a Isolated yield after purification unless otherwise noted. ^b Yield determined ¹H NMR of crude reaction mixture.

is generally tolerant of even electron-rich aromatics, although the product of substrate **22** was obtained only in low yield.

Notwithstanding the utility of these substituted 2,2dimethylbicyclo[3.3.1]nonan-9-ones, we hoped to expand the usefulness of this cyclization by varying the substitution of the olefin, thereby accommodating the construction of differentially substituted bicycles. Preliminarily, we sought to determine the effect (if any) that olefin substitution had on the regioselectivity of the cyclization. As illustrated in Table 3, we returned to the original model system, varying the alkenyl substituents.

Quite unexpectedly, these substituent changes caused a dramatic perturbation in cyclization selectivity. In fact, in

Table 3.	Effects	of Olefin	Substitution	on Cyclization
Regioselee	ctivity ^a			

R ₁ R ₁ R ₁ R ₁ R ₃ C		D ₂ Et <u>N-ł</u> Sr.	PSP nCl4	O PhSe R ₃ EtO ₂ C R ₂ ^{R₃} +	H^{1} R_{2} $CO_{2}Et$
				h	-
substrate	R ₁	R_2	R_3	C-Cyclized (%)	O-Cyclized (%)

^{*a*} Reaction conditions: 1.1 equiv of *N*-PSP, 1.0 equiv of SnCl₄, CH₂Cl₂, -23 °C, 15 min. ^{*b*} Isolated yield after purification unless otherwise noted. ^{*c*} Yield as a mixture of stereoisomers.

⁽¹¹⁾ Nicolaou, K. C.; Pastor, J.; Barluenga, S.; Winssinger, N. *Chem. Commun.* **1998**, 1947–1948. We thank N. Winssinger for the generous preparation of a sample of these resins.

all cases, except for the original model **12** and the crotyl substituted system **26**, the valuable preference for carboncentered cyclization was lost. Although a complete explanation of these results remains elusive, we have excluded the possibility that the substrates may be suffering cleavage of the enol acetate functionality prior to cyclization, as substrates treated with SnCl₄ under the same conditions but in the absence of *N*-PSP were recovered in greater than 90% yield in all cases. Hence, the results may be attributed to the sterics governing approach of the *epi*-selenium complex to the nucleophilic center.¹⁷

Last, with an improved understanding of the potential and limits of this cyclization in hand, we turned our attention toward solid-phase applications of the method. We previously reported the construction of polystyrene-based selenium bromide and selenium phthalimide resins;¹¹ consequently, we sought to determine whether such cyclization reactions might be amenable to the construction of resin-bound bicycles. Initially, we considered the simplified enol acetate **12** (see structure in Scheme 1) as a substrate for both resins. By using slightly longer reaction times (Table 4) and a 3-fold

Table 4. Solid-Phase Cyclization Reactions^a



substrate	X	time(min)	loading(%) °	purity(%) *
12	Phthalimide	20	0	na
12	Phthalimide	40	0	na
12	Br	20	83	98
14	Br	20	91	98
16	Br	20	81	85
19	Br	20	85	98
21	Br	20	55	80
23	Br	20	87	98
24	Br	20	90	98

^{*a*} Reaction conditions: 1.0 equiv of resin, 3.0 equiv of substrate, 3.0 equiv of $SnCl_4$, CH_2Cl_2 , -23 °C. ^{*b*} See Scheme 1, Table 1, and Table 2 for structure of substrates. ^{*c*} Loading is approximated by mass gain of resin assuming a functionalization of 1.76 mmol/g. ^{*d*} Purity determined by ¹H NMR of crude cleavage product [via oxidation-elimination protocol (Scheme 2)].

excess of substrate and SnCl₄, **12** was independently reacted with each resin in CH₂Cl₂. Subsequently, the resins were treated with *n*-Bu₃SnH and AIBN at 80 °C to affect cleavage of any reaction products. Gratifyingly, the reaction with the selenium bromide resin cleanly yielded the desired bicycle in 89% yield on the basis of theoretical resin loading. In contrast, the reaction with the selenium phthalimide resin produced no detectable bicyclic products. With the success of the former reagent, we attempted the cyclization of several representative substrates as illustrated in Table 4. Solution and solid-phase behavior were closely correlated in all cases. Besides acting as a robust tether, the selenium linker can undergo traceless or functionalizing cleavage as shown in Scheme 2. The versatility of these cleavage options coupled





^{*a*} Conditions: (a) 10.0 equiv of 30% H₂O₂, THF, 0 °C, 2 h; (b) CCl₄, 80 °C, 10 min; (c) 5.0 equiv of *n*-Bu₃SnH, 0.1 equiv of AIBN, C₆H₆, 80 °C, 2 h; (d) 5.0 equiv of *n*-Bu₃SnCH₂CH=CH₂, 0.1 equiv of AIBN, C₆H₆, 80 °C, 2 h.

with the economy of a single step loading/cyclization to produce resin-bound polyfunctionalized bicycles opens the possibility for the solid-phase synthesis of **1** and **2**, and more importantly, provides access to a novel class of rigid, carbocyclic scaffolds amenable to further combinatorial derivatization for the development of small molecule libraries.¹⁸

Acknowledgment. This work was supported by the National Institutes of Health, Bethesda, MD, The Skaggs Institute for Chemical Biology, and the Department of Defense (fellowship to J.P.).

Supporting Information Available: Representative procedures and spectral data for the preparation and cyclization of substrates **12**, **14** (solid phase), **15**, and **21**. This material is available free of charge via the Internet at http://pubs.acs.org.

OL990791D

⁽¹²⁾ Shamma, M.; Jones, C. D.; Weiss, J. A. Tetrahedron 1969, 25, 4743.

⁽¹³⁾ Review: Kozikowski, A. P.; Tuckmantel, W. Acc. Chem. Res. **1999**, *32*, to appear in the August issue on p 641 and available via ACS Articles ASAP until print publication.

⁽¹⁴⁾ Freed, M. E.; Potoski, J. R.; Freed, E. H.; Conklin, G. L. J. Med. Chem. 1973, 16, 595–599.

⁽¹⁵⁾ Gilbert, I. M.; Hewett, C. L.; Ree, D. R.; Redpath, J.; Savage, D. S.; Sleigh, T. J. Chem. Soc., Perkin Trans. 1 **1995**, 133–139.

⁽¹⁶⁾ For an example of the utility of the *gem*-dimethyl group in huperzine analogs, see: Kozikowski, A. P.; Ding, Q.; Saxena, A.; Doctor, B. P. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 259–262.

⁽¹⁷⁾ Molecular modeling studies are in progress.

⁽¹⁸⁾ Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gallop, M. A. *J. Med. Chem.* **1994**, *37*, 1385–1401. For a similar example, see: Ley, S. V.; Mynett, D. M.; Koot, W. J. *Synlett* **1995**, 1017–1020.